Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2022
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline UpdateN Lynn Henry, Mark R Somerfield, Zoneddy Dayao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2025
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast CancerPaula I Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L Maitland, Jasgit C Sachdev, Manish R Sharma, et al.British Journal of Cancer|November 6, 2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancerGiuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2023
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN TrialKevin Kalinsky, Melissa K Accordino, Codruta Chiuzan, et al.European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, et al.JAMA Oncology|June 14, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaPanagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.Pageof 3